BRPI0919236A8 - Terapêutica e vacinas de combinação de gas - Google Patents
Terapêutica e vacinas de combinação de gasInfo
- Publication number
- BRPI0919236A8 BRPI0919236A8 BRPI0919236A BRPI0919236A BRPI0919236A8 BR PI0919236 A8 BRPI0919236 A8 BR PI0919236A8 BR PI0919236 A BRPI0919236 A BR PI0919236A BR PI0919236 A BRPI0919236 A BR PI0919236A BR PI0919236 A8 BRPI0919236 A8 BR PI0919236A8
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines
- gas
- antigens
- combination therapeutic
- gas combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
VACINAS E SUBSTÂNCITAS TERAPÊUTICAS DE GAS COMBINADAS. Composições úteis para redução do risco, prevenção e/ou tratamento de infecções por S. pyogenes (GAS) que 5 compreendem combinações de antígenos de GAS, moléculas de ácido nucléico que codificam os antígenos ou anticorpos que se ligam especificamente aos antígenos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9755108P | 2008-09-17 | 2008-09-17 | |
PCT/IB2009/006949 WO2010076618A1 (en) | 2008-09-17 | 2009-09-17 | Combination gas vaccines and therapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0919236A2 BRPI0919236A2 (pt) | 2015-12-15 |
BRPI0919236A8 true BRPI0919236A8 (pt) | 2023-01-31 |
Family
ID=41508998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919236A BRPI0919236A8 (pt) | 2008-09-17 | 2009-09-17 | Terapêutica e vacinas de combinação de gas |
Country Status (18)
Country | Link |
---|---|
US (2) | US20100136041A1 (pt) |
EP (1) | EP2344523B1 (pt) |
JP (2) | JP5680536B2 (pt) |
CN (1) | CN102356090B (pt) |
AU (1) | AU2009334428B2 (pt) |
BR (1) | BRPI0919236A8 (pt) |
CA (1) | CA2737453A1 (pt) |
DK (1) | DK2344523T3 (pt) |
ES (1) | ES2566740T3 (pt) |
HR (1) | HRP20160306T1 (pt) |
HU (1) | HUE027618T2 (pt) |
MX (1) | MX2011002760A (pt) |
NZ (1) | NZ591633A (pt) |
PL (1) | PL2344523T3 (pt) |
SI (1) | SI2344523T1 (pt) |
SM (1) | SMT201600125B (pt) |
WO (1) | WO2010076618A1 (pt) |
ZA (1) | ZA201102005B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CN102971009A (zh) | 2009-10-30 | 2013-03-13 | 诺华有限公司 | 金黄色葡萄球菌5型和8型荚膜多糖的纯化 |
CN103239734B (zh) * | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | 用于预防和/或治疗呼吸道合胞病毒感染的疫苗 |
GB201206366D0 (en) * | 2012-04-11 | 2012-05-23 | Absynth Biologics Ltd | Bacterial vaccine |
MX363529B (es) * | 2012-09-18 | 2019-03-27 | Novartis Ag | Vesículas de membrana externa. |
MX2016013277A (es) | 2014-04-15 | 2017-01-18 | Univ Griffith | Vacuna para estreptococo de grupo a. |
BE1022553A1 (fr) * | 2014-05-07 | 2016-05-31 | Glaxosmithkline Biologicals Sa | Mutants de spy0269 |
US10329601B2 (en) * | 2015-12-28 | 2019-06-25 | Ionian Technologies, Inc. | Nicking and extension amplification reaction (NEAR) of Streptococcus species |
CN112442472B (zh) * | 2020-11-30 | 2023-05-26 | 四川大学华西医院 | 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法 |
JPWO2022158373A1 (pt) * | 2021-01-19 | 2022-07-28 | ||
GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
CN116875520B (zh) * | 2023-07-12 | 2024-06-14 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827038D0 (en) * | 1988-11-18 | 1988-12-21 | Kehoe M | Streptolysin o antigens & uses |
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
EP1648500B1 (en) * | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
EP1807446A2 (en) * | 2004-10-08 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
US20110038879A1 (en) * | 2006-10-30 | 2011-02-17 | Novartis Ag | Immunogenic and therapeutic compositions for streptococcus pyogenes |
AU2008299376B2 (en) * | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
KR101773114B1 (ko) * | 2007-12-21 | 2017-08-30 | 노파르티스 아게 | 스트렙토라이신 o의 돌연변이 형태 |
-
2009
- 2009-09-17 US US12/561,619 patent/US20100136041A1/en not_active Abandoned
- 2009-09-17 PL PL09786278.3T patent/PL2344523T3/pl unknown
- 2009-09-17 HU HUE09786278A patent/HUE027618T2/en unknown
- 2009-09-17 ES ES09786278.3T patent/ES2566740T3/es active Active
- 2009-09-17 EP EP09786278.3A patent/EP2344523B1/en active Active
- 2009-09-17 CA CA2737453A patent/CA2737453A1/en not_active Abandoned
- 2009-09-17 CN CN200980142304.9A patent/CN102356090B/zh active Active
- 2009-09-17 JP JP2011527423A patent/JP5680536B2/ja active Active
- 2009-09-17 BR BRPI0919236A patent/BRPI0919236A8/pt not_active Application Discontinuation
- 2009-09-17 AU AU2009334428A patent/AU2009334428B2/en active Active
- 2009-09-17 DK DK09786278.3T patent/DK2344523T3/da active
- 2009-09-17 NZ NZ591633A patent/NZ591633A/xx not_active IP Right Cessation
- 2009-09-17 MX MX2011002760A patent/MX2011002760A/es active IP Right Grant
- 2009-09-17 SI SI200931421A patent/SI2344523T1/sl unknown
- 2009-09-17 WO PCT/IB2009/006949 patent/WO2010076618A1/en active Application Filing
-
2011
- 2011-03-16 ZA ZA2011/02005A patent/ZA201102005B/en unknown
-
2014
- 2014-11-13 US US14/540,627 patent/US20150132337A1/en not_active Abandoned
- 2014-11-25 JP JP2014237470A patent/JP2015038156A/ja not_active Withdrawn
-
2016
- 2016-03-24 HR HRP20160306TT patent/HRP20160306T1/hr unknown
- 2016-04-29 SM SM201600125T patent/SMT201600125B/it unknown
Also Published As
Publication number | Publication date |
---|---|
JP5680536B2 (ja) | 2015-03-04 |
CN102356090B (zh) | 2016-01-20 |
US20150132337A1 (en) | 2015-05-14 |
PL2344523T3 (pl) | 2016-09-30 |
CA2737453A1 (en) | 2010-07-08 |
MX2011002760A (es) | 2011-06-16 |
AU2009334428B2 (en) | 2014-02-20 |
HRP20160306T1 (hr) | 2016-04-22 |
JP2015038156A (ja) | 2015-02-26 |
WO2010076618A1 (en) | 2010-07-08 |
DK2344523T3 (da) | 2016-04-18 |
AU2009334428A1 (en) | 2010-07-08 |
SMT201600125B (it) | 2016-07-01 |
EP2344523A1 (en) | 2011-07-20 |
ES2566740T3 (es) | 2016-04-15 |
JP2012502969A (ja) | 2012-02-02 |
HUE027618T2 (en) | 2016-11-28 |
ZA201102005B (en) | 2016-09-28 |
NZ591633A (en) | 2012-10-26 |
EP2344523B1 (en) | 2016-02-10 |
CN102356090A (zh) | 2012-02-15 |
BRPI0919236A2 (pt) | 2015-12-15 |
SI2344523T1 (sl) | 2016-06-30 |
US20100136041A1 (en) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919236A8 (pt) | Terapêutica e vacinas de combinação de gas | |
CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
CO6551686A2 (es) | Inmunoglobinas con dominio variable dual y usos de las mismas | |
BR112015013700A2 (pt) | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição | |
CU20180024A7 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas | |
CY1110860T1 (el) | Αναστροφη μεταγραφαση τελομερασης πτηνου | |
GB201020995D0 (en) | Biological materials and uses thereof | |
BR112015031883A2 (pt) | anti-pd-1 anticorpo e o uso dele | |
CL2008000935A1 (es) | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. | |
CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
BR112013003825A2 (pt) | conjugados, partículas, composições e métodos relacionados | |
UA104297C2 (en) | Anti-il-12/il-23 antibody | |
EA201491644A1 (ru) | Фармацевтические композиции | |
BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
EA201492101A1 (ru) | Антитела против fcrn | |
HN2012001223A (es) | Antagonistas de pcsk 9 | |
CL2008002083A1 (es) | Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
BR112015023797A2 (pt) | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 | |
EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
CL2008002085A1 (es) | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b | |
BR112013028655A8 (pt) | Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) |